CD38 and AL amyloidosis: Marketing authorizations were then obtained for (i) the anti-CD19 Tecartus® (brexucabtagene autoleucel) from Kite/Gilead (Foster City, California) in 2020 for relapsed or refractory (r/r) mantle cell lymphoma and for adult patients with r/r B-cell precursor ALL, and (ii) for the anti-B-cell maturation antigen (BCMA) Abecma® (idecabtagene vicleucel) from Celgene (Summit, New Jersey) in 2021 for the treatment of adult patients with r/r multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody.